Prostate cancer Posts - Page 6 of 80 on Medivizor
Navigation Menu

Prostate cancer Posts on Medivizor

Does nerve-sparing status impact surgical margin location for recurrence of prostate cancer after prostate surgery?

Does nerve-sparing status impact surgical margin location for recurrence of prostate cancer after prostate surgery?

Posted by on Aug 15, 2021 in Prostate cancer | 0 comments

In a nutshell This article looked at the impact of nerve-sparing (NS) surgery on positive surgical margin (PSM) location and the recurrence of tumors in patients following radical prostatectomy (RP; prostate removal surgery). The authors found that having NS surgery on both sides of the prostate increased the risk of PSM and was associated with a higher...

Read More

Is age associated with a poorer outcome for patients undergoing delayed prostate surgery following active surveillance?

Is age associated with a poorer outcome for patients undergoing delayed prostate surgery following active surveillance?

Posted by on Aug 8, 2021 in Prostate cancer | 0 comments

In a nutshell This study looked at whether age is related to a risk of poor outcomes in men undergoing delayed radical prostatectomy (RP; prostate removal surgery) following active surveillance (AS). The authors found that older patients require closer monitoring when on AS and may require additional testing to identify the progression of their...

Read More

Reducing unnecessary blood tests after robot assisted prostate surgery

Reducing unnecessary blood tests after robot assisted prostate surgery

Posted by on Aug 8, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the safety of eliminating routine postoperative blood tests after conducting robot-assisted radical prostatectomy (RARP) in patients with localized prostate cancer (PCa) and proposed recommendations for their use.  Some background Localized prostate cancer (PCa) refers to cancer that is confined to the prostate...

Read More

Evaluating real-world outcomes of abiraterone and enzalutamide in metastatic castrate-resistant prostate cancer

Evaluating real-world outcomes of abiraterone and enzalutamide in metastatic castrate-resistant prostate cancer

Posted by on Aug 7, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the real-world outcomes of two widely used drugs, abiraterone (Zytiga) and enzalutamide (Xtandi) in patients diagnosed with metastatic castrate-resistant prostate cancer (mCRPC). The study showed that both drugs were effective in these patients in a real-world setting, with better results...

Read More

Comparing outcomes for prostate surgery versus radiation therapy for localized prostate cancer

Comparing outcomes for prostate surgery versus radiation therapy for localized prostate cancer

Posted by on Jul 31, 2021 in Prostate cancer | 0 comments

In a nutshell The study aimed to compare the effectiveness of surgery versus radiation therapy for patients with high-grade localized prostate cancer (PCa). The study concluded that surgery was associated with improved survival compared to radiation therapy in these patients. Some background Prostate cancer (PCa) is the second most common...

Read More

Evaluating hypofractionated radiotherapy after prostate surgery in patients with prostate cancer.

Evaluating hypofractionated radiotherapy after prostate surgery in patients with prostate cancer.

Posted by on Jul 21, 2021 in Prostate cancer | 0 comments

In a nutshell This study investigated the outcomes of hypofractionated intensity-modulated radiation therapy (H-IMRT) to the prostate bed in patients with localized prostate cancer after prostate surgery. The data showed that H-IMRT after prostate surgery was safe and well-tolerated in these patients. Some background Localized prostate cancer...

Read More

Comparing darolutamide with apalutamide and enzalutamide for treating non-metastatic castration-resistant prostate cancer.

Comparing darolutamide with apalutamide and enzalutamide for treating non-metastatic castration-resistant prostate cancer.

Posted by on Jul 17, 2021 in Prostate cancer | 0 comments

In a nutshell The study compared the effectiveness and safety outcomes of darolutamide (Nubeqa) with apalutamide (Erleada) and enzalutamide (Xtandi) in treating non-metastatic castration-resistant prostate cancer (CRPC). The data showed that darolutamide was safer and had similar effectiveness compared to apalutamide and enzalutamide. Some background...

Read More

Comparing docetaxel to abiraterone in patients with metastatic castration-sensitive prostate cancer

Comparing docetaxel to abiraterone in patients with metastatic castration-sensitive prostate cancer

Posted by on Jul 11, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the effectiveness of docetaxel (DOC; Taxotere) to abiraterone (ABI; Zytiga) and assessed possible predictive markers of progression-free survival (PFS) in patients with metastatic castration-sensitive prostate cancer (mCSPC). The authors concluded that under real-world conditions, ABI was associated with...

Read More

Does androgen-deprivation therapy increase risk of mortality from heart attack or stroke?

Does androgen-deprivation therapy increase risk of mortality from heart attack or stroke?

Posted by on Jul 11, 2021 in Prostate cancer | 0 comments

In a nutshell This study examined the risk of heart-related mortality in patients undergoing androgen-deprivation therapy (ADT) for prostate cancer. It found that patients treated with radiation therapy and ADT did not have an increased risk of heart-related mortality. Some background Prostate cancer is often treated with radiation therapy to...

Read More

Evaluating the association between the lowest PSA value after prostate surgery and the occurrence of biochemical recurrence in patients with localized prostate cancer

Evaluating the association between the lowest PSA value after prostate surgery and the occurrence of biochemical recurrence in patients with localized prostate cancer

Posted by on Jul 11, 2021 in Prostate cancer | 0 comments

In a nutshell This study investigated the association between the lowest PSA value after radical prostatectomy (RP; surgery to remove the prostate) and the occurrence of biochemical recurrence (BCR) in patients with localized prostate cancer (PCa). The study found that a higher PSA value after RP and a shorter time to reach this...

Read More

Evaluating the effectiveness of salvage radiotherapy for recurrence after prostate surgery in patients with localized prostate cancer.

Evaluating the effectiveness of salvage radiotherapy for recurrence after prostate surgery in patients with localized prostate cancer.

Posted by on Jun 30, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness of salvage radiotherapy (RT) in patients with recurrence of prostate cancer (PCa) after prostate surgery. The study found that salvage RT was effective in the management of PCa recurrence with manageable side effects. Some background Localized prostate cancer (PCa) is a form of cancer that...

Read More

Does focal laser ablation improve outcomes in the long-term for patients with prostate cancer?

Does focal laser ablation improve outcomes in the long-term for patients with prostate cancer?

Posted by on Jun 30, 2021 in Prostate cancer | 0 comments

In a nutshell The study aimed to understand the long-term outcomes of focal laser therapy (FLT) in patients with prostate cancer. The study showed that this treatment has long-term survival without recurrence in certain patients.   Some background Surgical removal of the prostate gland is often recommended as a treatment for...

Read More